Travere Therapeutics (TVTX) announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, shares of its common stock. All of the shares are being offered by Travere. Jefferies and Leerink Partners are acting as the joint book-running managers for the offering.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $27 from $23 at Scotiabank
- Travere Therapeutics price target raised to $20 from $18 at Barclays
- Travere Therapeutics Boosts Sales with FILSPARI Approval
- Travere Therapeutics reports Q3 adjusted EPS (46c), consensus (68c)
- Travere presents data reinforcing clinical benefit of FILSPARI in IgAN